See more : Tastemaker Acquisition Corp. (TMKRU) Income Statement Analysis – Financial Results
Complete financial analysis of Bluejay Diagnostics, Inc. (BJDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bluejay Diagnostics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Alphaform AG (AFRMF) Income Statement Analysis – Financial Results
- Nocturne Acquisition Corporation (MBTCU) Income Statement Analysis – Financial Results
- Investis Holding SA (0RHV.L) Income Statement Analysis – Financial Results
- Asian Television Network International (ANI.BK) Income Statement Analysis – Financial Results
- OTR Acquisition Corp. (OTRA) Income Statement Analysis – Financial Results
Bluejay Diagnostics, Inc. (BJDX)
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 249.04K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 780.96K | 200.13K | 145.72K | 157.04K | 142.98K |
| Gross Profit | -780.96K | 48.91K | -145.72K | -157.04K | -142.98K |
| Gross Profit Ratio | 0.00% | 19.64% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.71M | 4.15M | 1.15M | 527.25K | 454.61K |
| General & Administrative | 4.31M | 4.76M | 1.79M | 596.12K | 884.00K |
| Selling & Marketing | 283.44K | 451.42K | 289.73K | 73.02K | 292.80K |
| SG&A | 4.60M | 5.21M | 2.08M | 669.14K | 1.18M |
| Other Expenses | 0.00 | 258.14K | -75.00K | 5.54K | 749.45K |
| Operating Expenses | 10.31M | 9.37M | 3.16M | 1.20M | 1.63M |
| Cost & Expenses | 10.31M | 9.57M | 3.16M | 1.20M | 1.63M |
| Interest Income | 164.90K | 89.67K | 513.30K | 143.67K | 52.28K |
| Interest Expense | 0.00 | 0.00 | 367.46K | 27.00K | 0.00 |
| Depreciation & Amortization | 780.96K | 306.37K | 145.72K | 157.04K | 142.98K |
| EBITDA | -9.17M | -8.99M | -3.08M | -1.04M | -1.49M |
| EBITDA Ratio | 0.00% | -3,637.82% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.31M | -9.32M | -3.23M | -1.20M | -1.63M |
| Operating Income Ratio | 0.00% | -3,741.48% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 357.33K | 20.83K | -258.14K | 38.11K | 811.57K |
| Income Before Tax | -9.95M | -9.30M | -3.49M | -1.16M | -819.84K |
| Income Before Tax Ratio | 0.00% | -3,733.11% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -69.06K | 241.39K | -32.57K | -62.13K |
| Net Income | -9.95M | -9.23M | -3.73M | -1.13M | -757.72K |
| Net Income Ratio | 0.00% | -3,705.38% | 0.00% | 0.00% | 0.00% |
| EPS | -72.62 | -73.22 | -29.67 | -14.19 | -9.55 |
| EPS Diluted | -72.62 | -73.22 | -29.67 | -14.19 | -9.55 |
| Weighted Avg Shares Out | 137.06K | 126.02K | 125.70K | 79.34K | 79.34K |
| Weighted Avg Shares Out (Dil) | 137.06K | 126.02K | 125.70K | 79.34K | 79.34K |
Bluejay Diagnostics Announces Reverse Stock Split
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
Bluejay Diagnostics Announces Reverse Stock Split
Source: https://incomestatements.info
Category: Stock Reports